Soft Robotic Heart Sleeve | Best Clinical Research Training Institute | Clinosol Research



Globally, 41 million people suffer from Heart Failure. Mechanical pumps known as Ventricular Assist Devices (VADs) that pump blood from the ventricles to the aorta and heart transplant are two of the current treatment options; while VADs are improving, patients are still at high risk for blood clots and stroke (brain attack).

Harvard researchers drew inspiration from the heart to build a completely new gadget that does not come into touch with blood. Soft pneumatic actuators put around the heart replicate the outer muscle layers of the human heart in the thin silicon sleeve. In a comparable motion to the beating heart, the actuators twist and compress the sleeve.

Working of Robotic Heart Sleeve:

This device is constructed of silicone, which contracts when exposed to air and expands when exposed to vacuum.

It is made to fit over the heart like a sleeve. The device swells and shrinks both circumferentially and helically, similar to the outermost layers of the human heart, which are made up of two layers of heart muscle that contract in opposite directions.

One pair of actuators expands and contracts concentrically, like rings on a barrel.

A separate layer of silicone contains a second set of actuators that expand and compress helically.

These two type of contraindications and expansions act together to pump blood through the mammalian heart.

A suction device, sutures, and a gel interface are used to adhere the sleeve to the heart, reducing friction between the device and the heart.

THE CLOT-BUSTER:

A soft robotic sleeve sits outside the heart. It is a 1.5 mm thick silicone sleeve.

The sleeve contracts as air is injected into the artificial muscles, which are arranged in bands, simulating the contraction of a heart.

Anti-clotting medications are not required because the device does not come into contact with blood like a traditional mechanical heart does.

ADVANTAGES:

Clot buster ( does not require blood thinners)

Improving cardiac function.

 

CLINICAL TRIALS:

On Pigs with Drug-Induced Heart Failure:

The device restored cardiac output to an average of roughly 97% of pre-failure levels in pigs with drug-induced heart failure, which lowered cardiac output to about 45% of baseline.

This device was tested on 6 pigs, which has cardiac arrest and was successful in getting all of their failed hearts to start pumping again.

Although this research is still in its early phases, it has a potential to keep human heart pumping in future.

CONCLUSION:

The novel ROBOTIC HEART SLEEVE could be used to help bridge the gap until a donor heart become available, or as a VAD during Heart Rehabilitation.

REFERENCES:

E. T. Roche, R. Wohlfarth, J. T. B. Overvelde, N.V. Vasilyev, F. A. Pigula, D. J. Mooney, K.Bertoldi, C.J.Walsh, A bioinspired soft actuated material. Adv. Mater. 26, 1200-1206(2014).

P. Polygerinous, Z. Wang, K. C. Galloway, R.J. Wood, C.J. Walsh, Soft robotic glove for combined assistance and at-home rehabilitation. Rob. Auton. Syst. 73, 135-143(2016).

R. Deimel, O. Brock, A novel type of compliant and underactuated robotic hand for dexterous grasping. Int. J. Rob. Res.35, 161-185.

Figures:

Figure 1: Ellen Roche/ Harvard John A. Paulson School of Engineering and Applied Sciences January 18, 2017

Figure 2: Scientific work published January 18, 2017 in the journal Science Translational Medicine.

Figure 3: Science Translational Medicine 18 January 2017 (Vol 9, Issue 373)


 https://www.clinosol.com/post/soft-robotic-heart-sleeve

Comments

Post a Comment

Popular posts from this blog

Safety Aggregate Reporting | Best Clinical Research Training Institute | Clinosol Research

Image
As the name suggests it is an aggregate (collection) of safety data of a particular drug, compiled and submitted periodically to the regulatory agencies to evaluate the risk- benefit balance of drug use. Compared with single case studies, aggregate reporting is stronger evidence concerning drug safety. Adverse drug reactions are one of the leading causes of morbidity and mortality worldwide. Safety aggregate reporting paves way to mitigate the risk of ADR caused by drugs, medical devices or biologicals. It focuses on encapsulating the safety data during both pre and post marketing phase. More importantly during the Post marketing phase, the incidence of time-related side effects can be keenly monitored. In early 1990s the Council for the Organization of Medical Sciences established a safety aggregate reporting techniques as follows: PSUR - Periodic Safety Update Report DSUR - Development Safety Update Report, that has been accepted and implemented widely in many countries under differ...
Read more

Automation in Pharmacovigilance | Best Clinical Research Training Institute | Clinosol Research

Image
  Automation in Pharmacovigilance Introduction       Per WHO definition, Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine/vaccine related problem. All medicines and vaccines undergo rigorous testing for safety and efficacy through clinical trials before they are authorized for use. It is a process of data acquisition (entry), data analysis and giving benefit risk communication. Here we will list out activities that are targets for automation in pharmacovigilance. In Data Acquisition (entry) Adverse event and serious adverse event collected and reported in safety database system. It is mostly transactional (exchange of data) In Data Analysis Internal data and external data surveillance occur by medical assessment and medical adjudication. It is mostly analytical and cognitive (intellectual) In Benefits Communication Risk mana...
Read more